Loading...
XSHG
600422
Market cap907mUSD
Jul 10, Last price  
8.28CNY
1D
-1.93%
1Q
-28.12%
Jan 2017
-39.82%
IPO
145.62%
Name

KPC Pharmaceuticals Inc

Chart & Performance

D1W1MN
XSHG:600422 chart
P/E
17.91
P/S
0.95
EPS
0.46
Div Yield, %
3.69%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
-3.15%
Revenues
6.58b
-21.72%
1,290,258,2401,310,931,3401,434,908,6641,817,237,6392,419,242,3753,016,021,7993,584,294,9184,315,764,7504,915,685,8735,100,597,1225,852,287,4327,101,977,6748,119,963,3197,717,086,9357,717,086,9358,253,532,5038,282,063,4568,430,177,0978,401,447,2336,576,664,100
Net income
350m
-46.00%
29,068,89132,118,03658,323,07985,577,950130,122,930181,750,111231,623,322288,836,483420,850,834407,256,148330,096,571335,535,847454,309,426456,856,228456,856,236507,667,606383,183,597540,710,573648,081,345349,940,800
CFO
289m
-64.21%
61,248,863130,059,18091,588,904128,569,83990,820,592140,236,287213,330,130241,969,668379,126,295476,617,134311,157,102242,534,997352,074,123429,500,909409,939,216251,628,491253,895,474754,330,498808,065,640289,236,102
Dividend
Jul 30, 20250.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

KPC Pharmaceuticals, Inc. operates as a pharmaceutical enterprise, with its operations spanning drug research and development, manufacturing, marketing, and wholesale distribution. The company serves both domestic markets within the People's Republic of China and international clientele. Its portfolio prominently features botanical drugs, including artemether, panax notoginseng, and gastrodine series medications. These, along with various Chinese and ethnic remedies—marketed under brand names such as Luotai, Tianxuanqing, Artemedine, Artem, and Arco—are deployed in the treatment of conditions affecting the cardiovascular and cerebrovascular systems, neurological disorders, and malaria. Beyond its herbal focus, KPC Pharmaceuticals supplies a broad range of healthcare products. These include Dai ethnic preparations, antibiotics, raw chemical materials, prepared chemical pharmaceuticals, traditional Chinese medicinal ingredients, biologicals, biochemical agents, and nutritional supplements. Specific offerings encompass Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, Ribavirin spray, glycyrrhizic acid, and the long-acting hypoglycemic GLP-1. Additionally, the company distributes artemisinin-based antimalarials, various generic medications, and medical devices. Established in 1951, the firm was initially known as Kunming Pharmaceutical Corporation before adopting its current name, KPC Pharmaceuticals, Inc., in April 2015. Its corporate headquarters are located in Kunming, situated in the People's Republic of China.
IPO date
Dec 06, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122021‑002020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT